Study of Adjunctive KarXT in subjects with inadequately controlled symptoms of schizophrenia (H-55189)

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia

Is your daily life being disrupted by the symptoms of schizophrenia?

The ARISE Study is looking at how safe a potential new drug is, and whether it works for people with schizophrenia when given with existing antipsychotic medications.

We are currently recruiting patients who:

• Are between 18 and 59 years of age (inclusive)
• Have been diagnosed with schizophrenia
• Already take antipsychotic medications, but still have symptoms.
• Have identified a reliable informant and/or clinical support team willing and able to assist with study activities

All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement for study-related time and travel may be provided.